Company Overview of Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States. The company’s lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber con...
11801 Research Drive
Alachua, FL 32615
Founded in 1999
Key Executives for Applied Genetic Technologies Corporation
Chief Executive Officer, President and Director
Total Annual Compensation: $313.9K
Chief Financial Officer
Total Annual Compensation: $175.0K
Chief Medical Officer and Vice President
Total Annual Compensation: $336.2K
Executive Director of Process Development
Total Annual Compensation: $122.4K
Compensation as of Fiscal Year 2014.
Applied Genetic Technologies Corporation Key Developments
Applied Genetic Technologies Corporation Announces Achievement of XLRS Patient Enrollment Milestone in Biogen Collaboration
Aug 27 15
Applied Genetic Technologies Corporation announced it had met a patient enrollment milestone in the X-Linked Retinoschisis (XLRS) clinical study, which will earn AGTC a $5 million payment from Biogen. AGTC filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in March to conduct a Phase I/II clinical trial of the company's gene therapy product candidate for the treatment of XLRS. Utilizing technology licensed from the University of Florida, AGTC's XLRS product candidate uses an AAV capsid with surface residues that have been specifically engineered for better penetration to the back of the eye. The primary clinical endpoint is safety and the secondary endpoints include assessments of visual acuity, visual field, ERG and optical coherence tomography. The study is expected to enroll a total of 27 patients at four sites and preliminary data from the first cohorts of patients are expected by the end of 2015. This marks the first milestone since AGTC and Biogen announced in July a broad collaboration agreement focused on the development of gene-based therapies for two orphan diseases of the retina and three options for early stage discovery programs in two ophthalmic and one non-ophthalmic condition. Biogen has completed the $124 million equity purchase and up-front payment, following the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the satisfaction of other customary closing conditions.
Applied Genetic Technologies Corporation Presents at BMO Capital Markets Biotech Corporate Access Day, Jul-28-2015
Jul 16 15
Applied Genetic Technologies Corporation Presents at BMO Capital Markets Biotech Corporate Access Day, Jul-28-2015 . Venue: Boston, Massachusetts, United States.
Applied Genetic Technologies Corporation Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-12-2015 09:45 AM
Jul 13 15
Applied Genetic Technologies Corporation Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-12-2015 09:45 AM. Venue: Le Parker Meridian, 119 West 56th Street, New York, NY 10019, United States. Speakers: Susan B. Washer, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 2, 2015